Report of Foreign Issuer (6-k)
April 03 2018 - 4:49PM
Edgar (US Regulatory)
United
States
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the Month of April, 2018
Commission File Number: 001-35892
GW
PHARMACEUTICALS PLC
(Translation of registrant’s name
into English)
Sovereign
House
Vision
Park
Histon
Cambridge
CB24 9BZ
United
Kingdom
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Notification of Interests of Directors,
Officers and Connected Persons
GW Pharmaceuticals plc (the “Company”)
hereby provides notification that on March 27, 2018, Julian Gangolli, President of the Company’s US Operations, exercised
options under the Company’s Long Term Incentive Plan and sold 1,110 American Depositary Shares (“ADSs”) at a
price of $114.56 per ADS in accordance with his Rule 10b5-1 plan established March 13, 2018. Further details are set forth in the
table below.
1.
|
Details of the person discharging managerial responsibilities / person closely associated
|
a.
|
Name
|
Julian Gangolli
|
2.
|
Reason for the notification
|
a.
|
Position/status
|
President of GW’s US Operations
|
b.
|
Initial notification
/Amendment
|
Initial notification
|
3.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
a.
|
Name
|
GW Pharmaceuticals PLC
|
b.
|
LEI
|
|
4.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
a.
|
Description of the
Financial instrument, type of instrument
Identification code
|
American Depositary Shares
ISIN: 36197T1034
|
b.
|
Nature of the transaction
|
Sell to cover transaction resulting in exercise of Long Term Incentive Plan options over 3,183 American Depositary Shares (ADSs) followed by sale of 1,110 ADSs in accordance with 10b5.1 plan dated 13 March 2018 to cover tax liability. Remaining 2,073 ADSs have been retained.
|
c.
|
Price(s) and volume(s)
|
Price(s)
$114.56
|
Volume(s)
1,110
|
ADS’s sold
|
d.
|
Aggregated information
¨
Aggregated volume
¨
Price
|
n/a
|
e.
|
Date of the transaction
|
27 March 2018
|
f.
|
Place of the transaction
|
Nasdaq, New York
|
For further information, please contact:
GW Pharmaceuticals PLC +44 (0)1980
557 000
Adam George, Company Secretary
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
GW Pharmaceuticals plc
|
|
|
|
|
By:
|
/s/ Adam George
|
|
Name:
|
Adam George
|
|
Title:
|
Company Secretary
|
|
|
|
Date: April 3, 2018
|
|
|